Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $12.00 | Buy | Rodman & Renshaw |
| 10/30/2024 | $12.00 | Buy | H.C. Wainwright |
| 9/24/2024 | $12.00 | Buy | Maxim Group |
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
10-K - FibroBiologics, Inc. (0001958777) (Filer)
SCHEDULE 13G - FibroBiologics, Inc. (0001958777) (Subject)
EFFECT - FibroBiologics, Inc. (0001958777) (Filer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b
HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team. "The addition of Ruben as our General Counsel rep
Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing Preparations for Phase 1/2 clinical trial in Australia utilizing CYWC628 to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 Cash and cash equivalents of approximately $14.0 million at December 31, 2024 HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic dis
HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025. About FibroBiologicsBased in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of tr
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The German-Nordic Joint Extracellular Matrix Meeting in Freiburg, Germany, from March 26-28, 2025. The joint meeting is an annual opportunity to showcase advances in extracellu
Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00